enVVeno Medical
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
70 Doppler, Irvine, California, 92618, U...Phone Number
(949) 261-2900Website
www.envveno.comRevenue
-Stock Symbol
NVNOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About enVVeno Medical
Based in Irvine, CA, enVVeno Medical (Nasdaq: NVNO) is a late clinical-stage medical device company developing bioprosthetic solutions to treat venous disease. Its lead product, the VenoValve, is a first-in-class surgical replacement valve for severe chronic venous insufficiency, and the company is also advancing enVVe, a non-surgical, transcatheter replacement valve aimed at the same condition.Explore more
enVVeno Medical Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is enVVeno Medical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at enVVeno Medical
enVVeno Medical, which may be a good buyer, showed buying intent in Masked Content Topic
Check if enVVeno Medical has recently received funding, and reach out quickly before it becomes old news!
Check out if enVVeno Medical is spiking on competitors!
Click to see if enVVeno Medical had a recent Job posting/layoffs
Earning: See what the market has to say on enVVeno Medical recently announced quarterly report
Product Launch: Get notified when enVVeno Medical launches new products
Funding: Get notified immidiatlly once enVVeno Medical has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined enVVeno Medical as Masked Content
Find 2 more new buyers
Compare Similar Companies to enVVeno Medical
Compare insights from companies similar to enVVeno Medical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
enVVeno Medical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
enVVeno Medical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about enVVeno Medical.
enVVeno Medical financials insights
Gather financial insights about enVVeno Medical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$680K
2017
Debt
$1M
2020
Debt
$150K
enVVeno Medical Tech Stack
A closer look at the technologies used by enVVeno Medical
Most Recent Scoops
Project
enVVeno Medical is currently enrolling patients in the ReNew Global Phase 2 trial, with 16 patients enrolled to date across five countries the U.S., Australia, UK, Poland, and Germany targeting up to 120 patients over 24 weeks of dosing, with an interim data readout expected before the end of this year and last patient, last visit estimated for summer of next year.
Clinical Operations
Project
enVVeno Medical is conducting the TAVI pivotal study for its enV system the final study required prior to FDA approval which will enroll 220 patients across 40 U.S. clinical sites, with enrollment expected to begin in Q4 of this year.
Clinical Operations
Project
enVVeno Medical has conducted preclinical testing of LTI-03 using a Precision Cut Lung Slicer tissue culture system with actual IPF biopsy tissue, demonstrating anti-fibrotic inhibition comparable to the market-leading drug and an increase in the viability of AEC2 lung progenitor cells at higher concentrations.
Medical Research, Pharmaceuticals
Project
enVVeno Medical has announced that by Q4 of this year, it expects to activate clinical sites, begin patient enrollment, and deliver an interim data readout for its TAVI pivotal study, with additional interim readouts planned throughout the course of the study.
Clinical Operations
Project
enVVeno Medical News & Media
enVVeno Medical Appoints New Chief Financial Officer - TipRanks.com
An update from enVVeno Medical ( ($NVNO) ) is now available. On May 19, 2025, enVVeno Medical Corporation appointed Jennifer Bright as its new Chief Financial Offic...enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Corsicana Daily Sun
IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deepenVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Yahoo Finance
IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as ...enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve® PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding enVVeno Medical
Sign Up For FreeTo access detailed company insights
Based in Irvine, CA, enVVeno Medical (Nasdaq: NVNO) is a late clinical-stage medical device company developing bioprosthetic solutions to treat venous disease. Its lead product, the VenoValve, is a first-in-class surgical replacement valve for severe chronic venous insufficiency, and the company is also advancing enVVe, a non-surgical, transcathete... Read More
